Search results
Showing 361 to 375 of 9042 results
All NICE products on drug misuse. Includes any guidance, advice and quality standards.
All NICE products on respiratory infections. Includes any guidance, advice and quality standards.
All NICE products on end of life care. Includes any guidance and quality standards.
All NICE products on health inequalities. Includes any guidance.
All NICE products on medicines management. Includes any guidance, advice and quality standards.
All NICE products on safeguarding. Includes any guidance and quality standards.
All NICE products on patient and service user care. Includes any guidance and quality standards.
All NICE products on mental health services. Includes any guidance and quality standards.
All NICE products on personality disorders. Includes any guidance and quality standards.
All NICE products on urinary incontinence. Includes any guidance, advice and quality standards.
All NICE products on chronic obstructive pulmonary disease. Includes any guidance, advice and quality standards.
All NICE products on upper gastrointestinal bleeding. Includes any guidance, advice and quality standards.
All NICE products on tuberculosis. Includes any guidance and quality standards.
All NICE products on influenza. Includes any guidance and quality standards.
This quality standard covers the care of women and their babies during labour and immediately after the birth. It covers women who go into labour at term, and includes women at low risk of complications during labour and those who go on to develop complications. It describes high-quality care in priority areas for improvement.
View quality statements for QS105Show all sections
Sections for QS105
- Quality statements
- Quality statement 1: Choosing birth setting
- Quality statement 2: One-to-one care
- Quality statement 3: Cardiotocography and initial assessment of a woman in labour
- Quality statement 4: Stopping cardiotocography
- Quality statement 5: Interventions during labour
- Quality statement 6: Delayed cord clamping
- Quality statement 7: Skin-to-skin contact